Share this article
Share this article
SAN DIEGO, May 27, 2021 /PRNewswire/ NeuraLace Medical, Inc., a medical device company focused on improving pain relief among patients suffering from debilitating chronic nerve pain, announced today that the first patient has been enrolled as part of the AXON-RCT U.S. study: a prospective, randomized, controlled clinical trial comparing the safety and effectiveness of Axon Therapy® for post-traumatic peripheral neuropathic pain to conventional medical management. The Primary Investigator of the study will be Dr. Leonardo Kapural of the Carolinas Pain Institute. We are incredibly excited to start our Axon-RCT study with Dr. Kapural s team to begin testing Axon Therapy on patients that suffer from chronic peripheral nerve pain, said Shiv Shukla, Founder and CEO of NeuraLace Medical.
First Patient Treated in Landmark U S Randomized Clinical Trial of NeuraLace s Chronic Pain Treatment streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Nevro Announces FDA Submission for HF10® Therapy in Patients with Painful Diabetic Neuropathy
SENZA-PDN Study is Largest Prospective, Multicenter, Randomized Clinical Trial of Spinal Cord Stimulation Conducted to Date
News provided by
Share this article
REDWOOD CITY, Calif., Dec. 28, 2020 /PRNewswire/
Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the company has submitted a pre-market approval supplement to the U.S. Food and Drug Administration (FDA) to seek approval of its Senza® System for the treatment of chronic pain associated with Painful Diabetic Neuropathy (PDN).